The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors by Arjun Mittra, Naoko Takebe, Vaia Florou, Alice P Chen, Abdul Rafeh Naqash

Get full text

Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature r... by Mona A. Marie, Justin D. McCallen, Zahra S. Hamedi, Abdul Rafeh Naqash, Abdul Rafeh Naqash, Alexander Hoffman, Druid Atwell, Suneetha Amara, Mahvish Muzaffar, Paul R. Walker, Paul R. Walker, Li V. Yang

Get full text

Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-in... by Abdul Rafeh Naqash, Danielle M. File, Carolyn M. Ziemer, Young E. Whang, Paula Landman, Paul B. Googe, Frances A. Collichio

Get full text

Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition by Abdul Rafeh Naqash, Ebenezer Appah, Li V. Yang, Mahvish Muzaffar, Mona A. Marie, Justin D. Mccallen, Shravanti Macherla, Darla Liles, Paul R. Walker

Get full text

Localized ablative immunotherapy drives de novo CD8+ T-cell responses to poorly immunogenic tumors by Mark M Davis, Saghar Kaabinejadian, Abdul Rafeh Naqash, Ashley R Hoover, Jason R Krawic, Xiao-Hong Sun, Qian Yin, Xinbo Yang, K Christopher Garcia, William H Hildebrand, Wei R Chen

Get full text

32 C-reactive protein (CRP) as a prognostic biomarker in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Results from a multi-center international ob... by Abdul Rafeh Naqash, Mahvish Muzaffar, Shravanti Macherla, Alessio Cortellini, James Clark, Emma Mi, Sanna Livanainen, Daria Gramenitskaya, Kevin O’Brien, Jussi Koivunen, Sweta Jonnalagadda, Shanker Polsani, Rahim Jiwani, Nitika Sharma, Chipman Stroud, Paul Walker, David Pinato

Molecular and immune landscape of tumours in geriatric patients with non-small cell lung cancer, melanoma and renal cell carcinoma by Abdul Rafeh Naqash, April K Salama, Emil Lou, Andrew Elliott, Wafik S El-Deiry, Chul Kim, Stephen V Liu, Anwaar Saeed, Hirva Mamdani, Khalil Choucair, Dipesh Uprety, Phillip Walker, Himisha Beltran, Matthew James Oberley, Azhar Saeed, Lujia Chen

Get full text

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden by Ignacio Garrido-Laguna, Asaf Maoz, Wungki Park, Abdul Rafeh Naqash, Vaia Florou, Breelyn Wilky, Jonathan Trent, Umang Swami, Garrett Frampton, Heloisa P Soares, Sonam Puri, Aik Choon Tan, Charalampos S Floudas, Carter Norton, Ethan S Sokol, Peter Hosein, Gilberto de Lima Lopes

Get full text

185 Global and local copy number aberration signatures as prognostic and immunotherapeutic predictors by Xuefeng Wang, Patrick Hwu, Igor Puzanov, Abdul Rafeh Naqash, Ahmad A Tarhini, George J Weiner, Margaret E Gatti-Mays, Howard Colman, Timothy I Shaw, Aakrosh Ratan, Martin D McCarter, John Carpten, Susanne M Arnold, Michelle Churchman, Tingyi Li, William S Dalton, Sijie Yao, Islam Eljilany

151 Genetic heterogeneity between paired primary and metastatic solid tumors and implications for neoantigen-based personalized cancer vaccines by Xuefeng Wang, Igor Puzanov, Abdul Rafeh Naqash, Paulo C Rodriguez, George J Weiner, Jose Conejo-Garcia, Jamie Teer, Xiaoqing Yu, Margaret E Gatti-Mays, William Dalton, Howard Colman, Aik Choon Tan, Timothy I Shaw, Darwin Chang, Alyssa Obermayer, Dale Hedges, Aakrosh Ratan, Martin D McCarter, John Carpten, Susanne M Arnold, Michelle Churchman

Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to Immunotherapy by Islam Eljilany, Sam Coleman, Aik Choon Tan, Martin D. McCarter, John Carpten, Howard Colman, Abdul Rafeh Naqash, Igor Puzanov, Susanne M. Arnold, Michelle L. Churchman, Daniel Spakowicz, Bodour Salhia, Julian Marin, Shridar Ganesan, Aakrosh Ratan, Craig Shriver, Patrick Hwu, William S. Dalton, George J. Weiner, Jose R. Conejo-Garcia, Paulo Rodriguez, Ahmad A. Tarhini

Get full text

Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune c... by Kun Wang, Sanna Iivanainen, Jussi Pekka Koivunen, Abdul Rafeh Naqash, Mahvish Muzaffar, Shravanti Macherla, James Clark, Joo Sang Lee, Eytan Ruppin, David J Pinato, Emma Mi, Daria Gramenitskaya, Sweta Jonnalagadda, Shanker Polsani, Paul R Walker, Justin D McCallen, Mona A Marie, Rahim Ali Jiwani, Maida Hafiz, Leonardo Brunetti, Chipman R G Stroud, Youngmin Chung, Li V Yang

Get full text

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study by Dominik Bettinger, Bo Yu, David Szafron, Yinghong Wang, Mahvish Muzaffar, Thomas Marron, Uqba Khan, Yi-Hsiang Huang, David J Pinato, Ahmed Kaseb, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, Musharraf Navaid, ChiehJu Lee, Anushi Bulumulle, Sonal Paul, Petros Fessas, Neil Nimkar, Hannah Hildebrand, Tiziana Pressiani, Yehia I Abugabal, Nicola Personeni, Lorenza Rimassa, Celina Ang, Abdul Rafeh Naqash, Francesca Benevento

Get full text

Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched s... by Dominik Bettinger, Masatoshi Kudo, Abdul Rafeh Naqash, Mahvish Muzaffar, Thomas Marron, Uqba Khan, Myron Schwartz, Yi-Hsiang Huang, David J Pinato, Anwaar Saeed, Hannah Hildebrand, Yehia I Abugabal, Celina Ang, Rahul Patel, Edward Kim, Naoshi Nishida, Ahmed O Kaseb, Anjana Pillai, Neha Debnath, Antonio D'Alessio, Brett Marinelli, Mario Cedillo, Ishan Sinha, Aaron Fischman, Vivian Bishay, Max Sung

Get full text

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors by Y. Linda Wu, Grace van Hyfte, Umut Özbek, Marlene Reincke, Anuhya Gampa, Yehia I. Mohamed, Naoshi Nishida, Brooke Wietharn, Suneetha Amara, Pei-Chang Lee, Bernhard Scheiner, Lorenz Balcar, Matthias Pinter, Arndt Vogel, Arndt Weinmann, Anwaar Saeed, Anjana Pillai, Lorenza Rimassa, Lorenza Rimassa, Abdul Rafeh Naqash, Mahvish Muzaffar, Yi-Hsiang Huang, Ahmed O. Kaseb, Masatoshi Kudo, David J. Pinato, Celina Ang

Get full text

Considerations for treatment duration in responders to immune checkpoint inhibitors by Daniel Olson, Jiajia Zhang, Todd Bartkowiak, Abdul Rafeh Naqash, Vaia Florou, Rosa Nguyen, Rania H Younis, Sarah Church, Maria E Rodriguez-Ruiz, Rachel Howard, Thomas U Marron, Ravi B Patel, Michal Sheffer, Abigail Overacre-Delgoffe, Aideen E Ryan, Sangeetha M Reddy, Sabina Kaczanowska, Dipti Thakkar, Kristin G Anderson, Esha Sachdev, Christopher Fuhrman, Jessica E Thaxton, David H Aggen, Jennifer L Guerriero

Get full text

Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy by Dominik Bettinger, Bo Yu, David Szafron, Yinghong Wang, Abdul Rafeh Naqash, Mahvish Muzaffar, Uqba Khan, Yi-Hsiang Huang, David J Pinato, Ahmed Kaseb, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, Musharraf Navaid, ChiehJu Lee, Anushi Bulumulle, Sonal Paul, Petros Fessas, Neil Nimkar, Hannah Hildebrand, Tiziana Pressiani, Yehia I Abugabal, Nicola Personeni, Jingky Lozano-Kuehne, Lorenza Rimassa, Celina Ang, Thomas U Marron

Get full text

898 Demonstration of the utility of real-world progression-free survival (rwPFS) by application of an IFN-γ-related signature in a real-world cohort of patients with melanoma by Xuefeng Wang, Igor Puzanov, Abdul Rafeh Naqash, Ahmad A Tarhini, George J Weiner, Phaedra Agius, Margaret E Gatti-Mays, Howard Colman, Aik Choon Tan, Issam El Naqa, Timothy I Shaw, Aakrosh Ratan, Martin D McCarter, John Carpten, Susanne M Arnold, Michelle Churchman, Michael D Radmacher, Oliver A Hampton, David M McKean, Daniel R Elgort, Robert J Rounbehler, Donghai Dai, Tingyi Li, William S Dalton

Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC by Rohini Sharma, Anjana Pillai, Thomas Urban Marron, Petros Fessas, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, David Szafron, Abdul Rafeh Naqash, Anuhya Gampa, Yinghong Wang, Uqba Khan, Mahvish Muzaffar, Chieh‐Ju Lee, Pei‐Chang Lee, Anushi Bulumulle, Sonal Paul, Dominic Bettinger, Hannah Hildebrand, Mohammed Yehia, Tiziana Pressiani, Ahmed Kaseb, Yi‐Hsiang Huang, Celina Ang, Masatoshi Kudo, Naoshi Nishida, Nicola Personeni, Lorenza Rimassa, David James Pinato

Get full text

448 Clinical outcomes and safety of immune checkpoint inhibitors (ICI) in patients with solid tumors and paraneoplastic syndromes (PNS) by Lucia Kwak, So Yeon Kim, Elad Sharon, Abdul Rafeh Naqash, Alessio Cortellini, Toni K Choueiri, Rana Mckay, Jeffrey A Sparks, Kaushal Parikh, Frank Aboubakar Nana, Jenny Linnoila, Shruti Gupta, Nicole R LeBoeuf, Elio Adib, Amin Nassar, Talal El Zarif, Ahmed Bilal Khalid, Serena J Rahme, Marita Salame, Elias Bou Farhat, Edward El Am, Arjun Ravishankar, Bachar Ahmad, David Kaldas, Andrea Malgeri, Ole-Petter R Hamnvik, Thomas Dilling, Elie Najem, Guru P Sonpavde